RA0276

antibody from Oursmab

Targeting: GP6 GPVI

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0276

Provider

Oursmab

Product name

Glenzocimab (Biosimilar Reference Antibody) (GP6)

Antibody type

Monoclonal

Description

Glenzocimab (development code ACT-017) is an investigational, humanized monoclonal antibody fragment (Fab) developed for the treatment of acute ischemic stroke and potentially other thrombotic conditions. It functions as a novel antiplatelet agent with a unique mechanism of action. Unlike traditional antiplatelet drugs that target platelet activation pathways (e.g., P2Y12 or COX-1 inhibition), glenzocimab is a selective inhibitor of platelet glycoprotein VI (GPVI). By binding to GPVI on the surface of platelets, it blocks the primary receptor for collagen, a key protein exposed at sites of vascular injury. This inhibition prevents collagen-induced platelet activation and thrombus formation without completely impairing hemostasis, aiming to reduce the risk of intracranial hemorrhage (bleeding), a major concern in stroke therapy.

Reactivity

Human

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.